Cortexyme Inc (NASDAQ: CRTX) has been a top performer since November, and this momentum increased in Friday’s session, when it closed the day with gains of 39.50%. In the past month, the company has had a series of good news, the more notable one being the announcement on December 7th that, it was presenting new data that supports the on-target activity of COR388.
COR388 is the company’s lead treatment that links the gingipain hypothesis for Alzheimer’s disease to the APOE gene as a key risk factor for Alzheimer’s. Speaking on this, the company’s Chief Medical Officer, Michael Detke stated that, the findings linked to an increasing interest in APOE fragmentation as a potential pathogen mechanism for Alzheimer’s.
In his presentation, Detke stated that, Gingipains from P.Gingivalis cut APOE proteins and that COR 388 prevents this from happening. He noted that, in experiments carried out by the company, cells that were infected with P. gingivalis showed gingipain-dependent APOE cleavage that led to fragments resembling those of people suffering from Alzheimer’s. He also noted that, CO388 was enough to block APOE fragmentation in the infected cells.
On top of that, COR388 showed a decrease in APOE fragments in CSF in phase-1b trial of the treatment. He noted that, the phase-1b clinical program for the treatment was made up of healthy volunteers and people that are suffering from Alzheimer’s disease. The treatment was assessed on its ability to inhibit APOE fragmentation in all the 9 test subjects. It was also assessed on its safety activity.
Commenting on the presentation, the company’s CEO, Casey Lynch stated that, the data presented gave insights into the reasons why APOE4 raises the risk of Alzheimer’s disease.
From a look at its price action, CRTX closed Friday’s session with significant gains, and on high volumes. It rallied by 39.50% to close the day at $66.08. Volumes in the day stood at 1.38 million.
About Cortexyme Inc
Cortexyme Inc is a biopharma company that develops treatments for Alzheimer’s and other degenerative diseases. It is based in San Francisco, Florida.